A Phase 2, Open-label, Single Dose, Study of Subcutaneously Administered ALN-CC5 in Patients with Paroxysmal Nocturnal Hemoglobinuria who are Inadequate Responders to Eculizumab
Phase of Trial: Phase II
Latest Information Update: 28 Dec 2016
At a glance
- Drugs ALN CC5 (Primary)
- Indications Paroxysmal nocturnal haemoglobinuria
- Focus Therapeutic Use
- Sponsors Alnylam Pharmaceuticals
- 23 Dec 2016 Status changed from recruiting to discontinued.
- 23 Aug 2016 New trial record
- 04 Aug 2016 According to an Alnylam Pharmaceuticals media release, this trial is expected to begin in the second half of 2016.